Lamotrigine oral suspension - Aucta Pharmaceuticals
Alternative Names: AUC-025; ET 105Latest Information Update: 03 Aug 2022
At a glance
- Originator Aucta Pharmaceuticals
- Class Antidepressants; Antiepileptic drugs; Chlorobenzenes; Mood stabilisers; Small molecules; Triazines
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Epilepsy
Most Recent Events
- 26 Jul 2022 No development reported - Preregistration for Epilepsy (Adjunctive treatment, In adolescents, In children, In the elderly, In adults) in USA (PO)
- 16 Mar 2022 Eton Pharmaceuticals anticipates regulatory approval for Epilepsy in USA (PO) in May 2022
- 31 Dec 2021 FDA assigns PDUFA action date of (30/05/2022) for lamotrigine oral suspension for Epilepsy (Form 10K, December 2021, Eton Pharmaceuticals)